Finally, since both PARP10 and PARP14 represent potential targets for cancer therapy, extensive characterization of PARP10 and PARP14 inhibitors in clinical settings is needed to determine therapeutic efficacy of these inhibitors. Here, PARP14 is linked to cancer.